H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most profitable biotech stocks to invest in now. On July 14, H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) and set a price target of $145.00.

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

Corcept Therapeutics Incorporated reported $157.2 million in revenue in fiscal Q1 2025 compared to $146.8 million in the same quarter last year.

Net income per common share (diluted) for the quarter was $0.17, compared to $0.25 in Q1 2024. The company also reiterated its 2025 revenue guidance of $900 million to $950 million.

Corcept Therapeutics Incorporated is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions.

The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.